Neoadjuvant treatment of HER2 and hormone-receptor positive breast cancer - Moving beyond pathological complete response

Serena Di Cosimo, Grazia Arpino, Daniele Generali

Research output: Contribution to journalArticle

Abstract

Pathologic complete response (pCR) was noted to be prognostic in all but hormone receptor-positive (HR) breast cancer cases even when HER2 is overexpressed. Evocative data suggest that HER2-positive breast cancer patients are a heterogeneous population and a subset of HER2-positive and HR-positive tumors biologically behave more like HER2-negative. Identification and targeted monitoring of these patients is crucial to consolidate data aiming to optimize combination treatment with new agents, thereby avoiding overtreatment with chemotherapy. The questions surrounding HER2-positive and HR-positive breast cancer patients treatment as well as the potential direction towards development of surrogate markers alternative to pCR are discussed.

Original languageEnglish
Pages (from-to)188-192
Number of pages5
JournalBreast
Volume23
Issue number2
DOIs
Publication statusPublished - 2014

Keywords

  • Breast cancer
  • HER2
  • Hormone receptor
  • Neoadjuvant therapy
  • Targeted therapy
  • Trastuzumab

ASJC Scopus subject areas

  • Surgery
  • Medicine(all)

Fingerprint Dive into the research topics of 'Neoadjuvant treatment of HER2 and hormone-receptor positive breast cancer - Moving beyond pathological complete response'. Together they form a unique fingerprint.

  • Cite this